Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2666 USD | -0.22% | -1.26% | -2.98% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.98% | 101M | - | ||
+13.25% | 2.91B | D+ | ||
+14.12% | 1.69B | - | ||
+84.57% | 625M | - | ||
+3.64% | 485M | - | ||
+29.11% | 159M | - | ||
+13.51% | 108M | - | - | |
+52.81% | 56.96M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- MRMD Stock
- Ratings MariMed Inc.